{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:45:57Z","timestamp":1790214357357,"version":"4.1.0"},"reference-count":47,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.3892\/ijmm.2015.2411","type":"journal-article","created":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T08:47:17Z","timestamp":1447404437000},"page":"3-10","source":"Crossref","is-referenced-by-count":11,"title":["Repositioning of drugs using open-access data portal DTome: A test case with probenecid (Review)"],"prefix":"10.3892","volume":"37","author":[{"given":"MOHAMMAD U.","family":"AHMED","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DYLAN J.","family":"BENNETT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TZE-CHEN","family":"HSIEH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BARBARA B.","family":"DOONAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SABA","family":"AHMED","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOSEPH M.","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,11,13]]},"reference":[{"key":"key20180107234549_b1-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7326\/0003-4819-145-10-200611210-00024","article-title":"Alterations in processes and priorities needed for new drug development","volume":"145","author":"Wilson","year":"2006","journal-title":"Ann Intern Med"},{"key":"key20180107234549_b2-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0197-2456(99)00009-4","article-title":"False positive rates of randomized phase II designs","volume":"20","author":"Liu","year":"1999","journal-title":"Control Clin Trials"},{"key":"key20180107234549_b3-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/clpt.2009.293","article-title":"Deconstructing the drug development process: The new face of innovation","volume":"87","author":"Kaitin","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"key20180107234549_b4-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107234549_b5-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/0022-3859.81870","article-title":"Drug repositioning: Re-investigating existing drugs for new therapeutic indications","volume":"57","author":"Padhy","year":"2011","journal-title":"J Postgrad Med"},{"key":"key20180107234549_b6-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.1158140","article-title":"Drug target identification using side-effect similarity","volume":"321","author":"Campillos","year":"2008","journal-title":"Science"},{"key":"key20180107234549_b7-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"key20180107234549_b8-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"key20180107234549_b9-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"Sirota","year":"2011","journal-title":"Sci Transl Med"},{"key":"key20180107234549_b10-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003088-198106020-00004","article-title":"Clinical pharmacokinetics of probenecid","volume":"6","author":"Cunningham","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"key20180107234549_b11-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","article-title":"The history and future of probenecid","volume":"12","author":"Robbins","year":"2012","journal-title":"Cardiovasc Toxicol"},{"key":"key20180107234549_b12-ijmm-37-01-0003","first-page":"80","article-title":"Renal transport of urate in humans","volume":"14","author":"Roch-Ramel","year":"1999","journal-title":"News Physiol Sci"},{"key":"key20180107234549_b13-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","article-title":"Update on gout: New therapeutic strategies and options","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"key20180107234549_b14-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrrheum.2014.32","article-title":"Optimizing current treatment of gout","volume":"10","author":"Rees","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"key20180107234549_b15-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20180107234549_b16-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.pop.2010.07.008","article-title":"Crystal arthropathies: Recognizing and treating 'the gouch'","volume":"37","author":"Quillen","year":"2010","journal-title":"Prim Care"},{"key":"key20180107234549_b17-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3810\/psm.2011.11.1946","article-title":"2011 recommendations for the diagnosis and management of gout and hyperuricemia","volume":"39","author":"Hamburger","year":"2011","journal-title":"Phys Sportsmed"},{"key":"key20180107234549_b18-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2509","article-title":"Developments in the scientific and clinical understanding of gout","volume":"10","author":"So","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"key20180107234549_b19-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pharmthera.2005.07.005","article-title":"Human renal organic anion transporters: Characteristics and contributions to drug and drug metabolite excretion","volume":"109","author":"Robertson","year":"2006","journal-title":"Pharmacol Ther"},{"key":"key20180107234549_b20-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"key20180107234549_b21-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000184368","article-title":"Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test","volume":"46","author":"Garyfallos","year":"1987","journal-title":"Nephron"},{"key":"key20180107234549_b22-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/archinte.1955.00250070099012","article-title":"Probenecid (benemid); its uses and side-effects in 2,502 patients","volume":"95","author":"Boger","year":"1955","journal-title":"AMA Arch Intern Med"},{"issue":"Suppl 6","key":"key20180107234549_b23-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/ard.25.Suppl_6.623","article-title":"Comparison of allopurinol and probenecid","volume":"25","author":"Scott","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"key20180107234549_b24-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"J Rheumatol"},{"issue":"Suppl 9","key":"key20180107234549_b25-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2105-13-S9-S7","article-title":"DTome: A web-based tool for drug-target interactome construction","volume":"13","author":"Sun","year":"2012","journal-title":"BMC Bioinformatics"},{"key":"key20180107234549_b26-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"key20180107234549_b27-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2125.2009.03564.x","article-title":"Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid","volume":"69","author":"Landersdorfer","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"key20180107234549_b28-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1074\/jbc.M708615200","article-title":"Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination","volume":"283","author":"Truong","year":"2008","journal-title":"J Biol Chem"},{"key":"key20180107234549_b29-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neulet.2012.11.027","article-title":"Organic anion transport pathways in antiviral handling in choroid plexus in Oat1 (Slc22a6) and Oat3 (Slc22a8) deficient tissue","volume":"534","author":"Nagle","year":"2013","journal-title":"Neurosci Lett"},{"key":"key20180107234549_b30-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"26934","DOI":"10.1074\/jbc.M203803200","article-title":"Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice","volume":"277","author":"Sweet","year":"2002","journal-title":"J Biol Chem"},{"key":"key20180107234549_b31-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"F972","DOI":"10.1152\/ajprenal.00356.2003","article-title":"Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice","volume":"286","author":"Sykes","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"key20180107234549_b32-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/00002030-200307040-00008","article-title":"Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters","volume":"17","author":"Strazielle","year":"2003","journal-title":"AIDS"},{"key":"key20180107234549_b33-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jps.2600780903","article-title":"Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit","volume":"78","author":"Hedaya","year":"1989","journal-title":"J Pharm Sci"},{"key":"key20180107234549_b34-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0140-6736(90)91116-R","article-title":"Zidovudine with probenecid: A warning","volume":"335","author":"Petty","year":"1990","journal-title":"Lancet"},{"key":"key20180107234549_b35-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0091270002239705","article-title":"Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis","volume":"43","author":"Wolf","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"key20180107234549_b36-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1128\/AAC.00047-08","article-title":"Pharmacokinetics and tolerability of oseltamivir combined with probenecid","volume":"52","author":"Holodniy","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key20180107234549_b37-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/AAC.01532-12","article-title":"Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy","volume":"57","author":"Perwitasari","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key20180107234549_b38-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"29184","DOI":"10.1074\/jbc.M112.377176","article-title":"Loss of pannexin 1 attenuates melanoma progression by reversion to a melanocytic phenotype","volume":"287","author":"Penuela","year":"2012","journal-title":"J Biol Chem"},{"key":"key20180107234549_b39-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"C752","DOI":"10.1152\/ajpcell.00228.2008","article-title":"P2X7 receptor-Pannexin1 complex: Pharmacology and signaling","volume":"295","author":"Iglesias","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"key20180107234549_b40-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1523\/JNEUROSCI.3295-09.2010","article-title":"P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide","volume":"30","author":"Clark","year":"2010","journal-title":"J Neurosci"},{"key":"key20180107234549_b41-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"31447","DOI":"10.1074\/jbc.M113.467753","article-title":"Determinants of 14-3-3\u03c3 protein dimerization and function in drug and radiation resistance","volume":"288","author":"Li","year":"2013","journal-title":"J Biol Chem"},{"key":"key20180107234549_b42-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"21639","DOI":"10.1074\/jbc.M203167200","article-title":"Identification of 14-3-3zeta as a protein kinase B\/Akt substrate","volume":"277","author":"Powell","year":"2002","journal-title":"J Biol Chem"},{"key":"key20180107234549_b43-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/542","article-title":"ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins","volume":"19","author":"Waterman","year":"1998","journal-title":"Nat Genet"},{"key":"key20180107234549_b44-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1681\/ASN.2005030306","article-title":"Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins","volume":"16","author":"Miyazaki","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key20180107234549_b45-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"30429","DOI":"10.1074\/jbc.272.48.30429","article-title":"Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine\/threonine kinase activities","volume":"272","author":"Couet","year":"1997","journal-title":"J Biol Chem"},{"key":"key20180107234549_b46-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1124\/dmd.111.040295","article-title":"PDZK1 regulates breast cancer resistance protein in small intestine","volume":"39","author":"Shimizu","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"key20180107234549_b47-ijmm-37-01-0003","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.103.054304","article-title":"Functional expression of the multidrug resistance protein 1 in microglia","volume":"307","author":"Dallas","year":"2003","journal-title":"J Pharmacol Exp Ther"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijmm.2015.2411\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T19:21:10Z","timestamp":1515352870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2015.2411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,11,13]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.3892\/ijmm.2015.2411"],"URL":"https:\/\/doi.org\/10.3892\/ijmm.2015.2411","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,13]]}}}